Comparative efficacy of levofloxacin and ceftriaxone in the treatment of community acquired pneumonia in children
Abstract
Pneumonia is a common cause of mortality and morbidity
in under-5 children throughout the world. Globally an estimated 156 million new
episodes of pneumonia occur each year in children and 2 million children die
from pneumonia each year which is 20 percent of all deaths of children under
five years old. Ceftriaxone is a commonly used drug for empiric treatment of
community acquired pneumonia (CAP) in children. Levofloxacin may be an adequate
option for empiric therapy in treatment of CAP in children because it gives the
broad spectrum activity against both bacterial and atypical pathogens causing
CAP and studies suggest that it can be safely used in children. This open
labeled, randomized, comparative clinical trial was carried out in the Department
of Pediatrics, Sylhet MAG Osmani Medical College Hospital, Bangladesh during
January, 2011 & December, 2012 to compare the efficacy of levofloxacin and
ceftriaxone in the treatment CAP in children. A total 70 cases of CAP were
enrolled. 35 cases were allocated to levofloxacin group and another 35 cases to
ceftriaxone group. At first the study cases were selected by systematic random
sampling. Group allocation to either levofloxacin or ceftriaxone group was done
by lottery method. Total duration for receiving study drugs was seven days.
Dose of levofloxacin was 10 mg/kg/day children ≥5 years, where as it was 10 mg/kg
12 hourly in 6 months to Clinical
responses were categorized as cured and treatment failure. 91.43% cases
were…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.